Home » Topics » BioWorld Science

BioWorld Science
RSS

Bristol-Myers Squibb: Q3 1997 highlights

Nov. 18, 1997

Merck & Co. isolates novel antifungal agent with potent, broad-spectrum activity

Nov. 18, 1997

Second-generation, highly selective COX-2 inhibitors developed at Merck

Nov. 18, 1997

LXR's patented drug screening technology yields two novel apoptosis-suppressing agents

Nov. 18, 1997

Second report of clinical efficacy for rotavirus vaccine

Nov. 18, 1997

SomatoKine shows potential for the treatment of osteoporosis

Nov. 18, 1997

FDA clears new Tilade formulation

Nov. 18, 1997

TpP, FiF introduced to medical community at major trade show

Nov. 18, 1997

Safety, immunogenicity and efficacy of anti-TNF antibody in RA patients

Nov. 18, 1997

Data presented on Shionogi's S-2150

Nov. 18, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 22, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 22, 2025.
In 2025, science’s biggest story was political
BioWorld
In 2025, science saw its breakthroughs, which BioWorld will be covering as part of our end-of-the-year wrap-up. But the biggest science story of 2025 is not about...
FDA says yes to Cytokinetics’ aficamten, now Myqorzo, in oHCM
BioWorld
Cytokinetics Inc. scored U.S. FDA marketing clearance Dec. 19 for Myqorzo (aficamten) 5-mg, 10-mg, 15-mg, and 20-mg tablets to improve functional capacity and...
Conjugating ferrocene to GPX4 inhibitors to promote ferroptosis
BioWorld Science
Small molecules that induce iron-dependent oxidative cell death known as ferroptosis can be effective against tumors that are resistant to other therapies....